Colossal's ambitious de-extinction goals serve as an 'Apollo-esque' mission, forcing rapid innovation across the entire biotech stack. This includes advancements in multiplex gene editing, ancient DNA assembly, AI-driven computational biology, lab automation, and novel reproductive technologies like artificial wombs.
The company is pioneering a new model for funding large-scale conservation. It combines near-term revenue from technology spin-outs with a long-term vision of generating recurring revenue from ecosystem restoration, funded by emerging markets for biodiversity credits, carbon credits, and enhanced ecotourism.
A core scientific challenge is translating fragmented ancient DNA into a living animal. The process involves sequencing dozens of ancient genomes, identifying the key genetic differences that confer extinct traits, and then precisely engineering the genome of a close living relative (e.g., editing an Asian elephant to express mammoth traits).
Operating at the edge of scientific possibility requires navigating complex ethical questions (e.g., 'playing God') and a shifting regulatory landscape, such as the FDA's historical view of gene-edited animals as drugs. Colossal addresses this through public engagement, open-sourcing conservation tech, and establishing clear internal ethical lines, such as not working on human or non-human primate species.
Keep pulling the thread on Ben Lamm.